NEWS ON HEALTH CARE
-
May 20, 2022, Friday
Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%
Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
-
May 20, 2022, Friday
Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
-
May 20, 2022, Friday
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
-
May 20, 2022, Friday
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
-
May 19, 2022, Thursday
Dr Reddy's plans new brands in Russia, says no issue with funds in country
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
-
May 19, 2022, Thursday
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
-
May 19, 2022, Thursday
Lupin slips 9%, hits 2-year low on disappointing March quarter results
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than ...
-
May 19, 2022, Thursday
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
-
May 19, 2022, Thursday
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
-
May 19, 2022, Thursday
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
-
May 19, 2022, Thursday
Rejuvenating Cipla: After global expansion, acquisitions on cards
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
-
May 18, 2022, Wednesday
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
-
May 18, 2022, Wednesday
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from ...
-
May 17, 2022, Tuesday
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
-
May 17, 2022, Tuesday
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March ...
-
May 17, 2022, Tuesday
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major ...
-
May 16, 2022, Monday
USFDA rush after 2-year lull: 20-30% new products may be open to inspection
The last two years saw limited physical inspections due to travel restrictions during the pandemic
-
May 13, 2022, Friday
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of ...
-
May 12, 2022, Thursday
Cipla looks to invest more in mRNA tech; holds discussions with firms
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed ...
-
May 11, 2022, Wednesday
Cipla will use Covid-19 bulk drugs inventory when demand rises
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
-
May 11, 2022, Wednesday
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4
In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
-
May 11, 2022, Wednesday
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun
Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory ...
-
May 10, 2022, Tuesday
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact
For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
-
May 10, 2022, Tuesday
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far
Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
-
May 10, 2022, Tuesday
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
-
May 10, 2022, Tuesday
Rainbow Children's Medicare lists at 7% discount to issue price
The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
-
May 06, 2022, Friday
75% of Nifty50 stocks trade below 200-DMA; look weak on the charts
Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent ...
-
May 05, 2022, Thursday
Sanofi India: Strong balance sheet, high cash reserves positives for stock
Products in the price control list and growth of the non-power brand portfolio will be key monitorables
-
May 05, 2022, Thursday
Pfizer sets up drug development centre at Chennai's IIT Research Park
The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global ...
-
May 04, 2022, Wednesday
Zomato, L&T Infotech, Solara, TTML plunge over 25% in one month
Shares of Zomato hit a new low of Rs 64.70, down 7 per cent on the BSE in Wednesday's intra-day trade
-
May 02, 2022, Monday
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow
During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals
-
May 02, 2022, Monday
Solara Active Pharma slips 15% after Rajender Rao resigns as MD & CEO
Jitesh Devendra, former CEO and Managing Director (MD) of the company will return to Solara as MD, to steer the reset strategy of the Company
-
April 21, 2022, Thursday
Gland Pharma advances 9% on heavy volumes; stock hits 9-week high
At 09:15 AM; around 5.42 million equity shares, representing 3.3 per cent of total equity of Gland Pharma, changed hands on the BSE
-
April 20, 2022, Wednesday
Cost pressure likely to weigh on pharma companies' margins in Q4
Among Indian firms, Edelweiss feels that Cipla (respiratory) and Sun Pharma (specialty) are better placed to tide the price erosion
-
April 19, 2022, Tuesday
Growth trajectory, margins anc client additions to sustain for Laurus Labs
Some of the growth is captured in the price rally, higher valuations
-
April 18, 2022, Monday
Sanofi India names Rodolfo Hrosz managing director effective June 1
He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are ...
-
April 14, 2022, Thursday
Lupin receives USFDA approval for anti-depressant drug
It is the generic equivalent of Pristiq, extended-release tablets, 25 mg of PF PRISM C.V, it added
-
April 12, 2022, Tuesday
Gufic Biosciences soars 14%, hits 52-week high on improved business outlook
Rating agency CRISIL Ratings has revised the company's outlook on the long-term bank facilities
-
April 11, 2022, Monday
Glenmark to conduct clinical trials of its molecule on cancer patients
Glenmark Pharmaceuticals on Monday said its unit has received approval from the DCGI to conduct phase 1 clinical trials of its novel molecule on ...
-
April 05, 2022, Tuesday
Over half of Nifty500 stocks trade above 200-DMA; analysts see more upside
Nifty 50 is back to 18,000, still half of Nifty 500 stocks trade below 200-DMA
-
March 31, 2022, Thursday
KKR affiliate sells 10% stake in Max Healthcare for nearly Rs 3,300 cr
It sold shares at Rs 340 a apiece to a clutch of investors, which included SBI Mutual Fund, Pension Fund Global and Smaller Cap World Fund
